|
|
|
|
| LEADER |
00000nam a2200000 i 4500 |
| 001 |
in00006320149 |
| 006 |
m o d f |
| 007 |
cr b|||||a|||| |
| 008 |
210707s2018 dcua ob f000 0 eng c |
| 005 |
20230201165350.6 |
| 035 |
|
|
|a (OCoLC)on1259368245
|
| 042 |
|
|
|a pcc
|
| 043 |
|
|
|a n-us---
|
| 040 |
|
|
|a GPO
|b eng
|e rda
|e pn
|c GPO
|d GPO
|d MvI
|
| 049 |
|
|
|a TXME
|
| 050 |
|
4 |
|a KF27
|b .E553 2017h
|
| 074 |
|
|
|a 1019-C-01 (online)
|
| 086 |
0 |
|
|a Y 4.C 73/8:115-10
|
| 088 |
|
|
|a Serial no. 115-10 (United States. Congress. House. Committee on Energy and Commerce)
|
| 099 |
|
|
|a Online Government Document
|
| 110 |
1 |
|
|a United States.
|b Congress.
|b House.
|b Committee on Energy and Commerce.
|b Subcommittee on Health,
|e author.
|
| 245 |
1 |
0 |
|a Examining FDA's generic drug and biosimilar user fee programs :
|b hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, March 2, 2017.
|
| 246 |
3 |
|
|a Examining Food and Drug Administration's generic drug and biosimilar user fee programs
|
| 264 |
|
1 |
|a Washington :
|b U.S. Government Publishing Office,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (v, 136 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 500 |
|
|
|a "Serial No. 115-10."
|
| 588 |
|
|
|a Description based on online resource, PDF version; title from title page (govinfo, viewed July 7, 2021).
|
| 610 |
1 |
0 |
|a United States.
|b Food and Drug Administration
|x Rules and practice.
|
| 610 |
1 |
7 |
|a United States.
|b Food and Drug Administration.
|2 fast
|0 (OCoLC)fst00549734
|
| 650 |
|
0 |
|a Generic drugs
|x Prices
|z United States.
|
| 650 |
|
0 |
|a Prescription pricing
|x Law and legislation
|z United States.
|
| 650 |
|
0 |
|a User charges
|x Law and legislation
|z United States.
|
| 650 |
|
0 |
|a Drug accessibility
|x Government policy
|z United States.
|
| 650 |
|
0 |
|a Drugs
|x Law and legislation
|z United States.
|
| 655 |
|
7 |
|a Legislative hearings.
|2 lcgft
|
| 776 |
0 |
8 |
|i Print version:
|a United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.
|t Examining FDA's generic drug and biosimilar user fee programs
|w (DLC) 2018439914
|w (OCoLC)1078699092
|
| 856 |
4 |
0 |
|z CONNECT
|u https://purl.fdlp.gov/GPO/gpo157392
|t 0
|
| 910 |
|
|
|a MTUSM2108
|
| 910 |
|
|
|a DWS
|
| 922 |
|
|
|a BIBCONEW
|b 20210707
|
| 999 |
f |
f |
|s 8468ad7d-b659-430c-ae82-70a9a5b4b02e
|i 2b7c1d7e-1a11-47ae-9aac-6b3538dfc98d
|t 0
|
| 952 |
f |
f |
|a Middle Tennessee State University
|b Main
|c James E. Walker Library
|d Electronic Resources
|t 0
|e Y 4.C 73/8:115-10
|h Superintendent of Documents classification
|
| 856 |
4 |
0 |
|t 0
|u https://purl.fdlp.gov/GPO/gpo157392
|z CONNECT
|
